38 results
8-K
EX-99.1
NAMS
NewAmsterdam Pharma Company N.V.
7 Aug 24
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
8:00am
, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN trial, evaluating obicetrapib as monotherapy or combination therapy, the Company observed
8-K
EX-99.1
NAMS
NewAmsterdam Pharma Company N.V.
29 Jul 24
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial
8:30am
, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN trial, evaluating obicetrapib as monotherapy or combination therapy, the Company
8-K
EX-99.1
NAMS
NewAmsterdam Pharma Company N.V.
11 Jun 24
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United
8:12am
, TULIP, ROSE, and OCEAN, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering
8-K
EX-99.1
NAMS
NewAmsterdam Pharma Company N.V.
9 May 24
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
8:00am
to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, evaluating obicetrapib
10-Q
0lipq17hc0a5ksmr
8 May 24
Quarterly report
4:30pm
8-K
EX-99.1
bm7620okqj2 sajtjp
28 Feb 24
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
8:11am
10-K
yv9t5j8e7ksfq7 8o
28 Feb 24
Annual report
8:00am
424B5
2qid0x
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
v6uan
13 Feb 24
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
khrvesyl d4018s
22 Jan 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
n8lb beayb7
8 Jan 24
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
8:21am
8-K
EX-99.1
pcsrxidje
8 Jan 24
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
8:21am
8-K
EX-99.1
uwlju88 0483
4 Jan 24
NewAmsterdam Pharma Announces 2024 Strategic Priorities
8:08am
424B3
x8xn2rtub1
19 Dec 23
Prospectus supplement
4:36pm
F-3
j0wsj37m
7 Dec 23
Shelf registration (foreign)
4:16pm
6-K
EX-99.1
lojlzr w7txvru8
13 Nov 23
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
12:00am
6-K
EX-99.1
a2ocfudt
25 Sep 23
Current report (foreign)
8:10am
6-K
EX-99.1
af0rbkd9xjy ns
21 Sep 23
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients
7:14am
424B3
xb3cc3
15 Aug 23
Prospectus supplement
4:52pm